Skip to main content
Glama

Company Compliance Timeline

fda_company_compliance_timeline
Read-onlyIdempotent

Build a reverse-chronological compliance timeline for one company and any linked subsidiaries. Combines inspections, warning letters, import alerts, import refusals, debarments, and recall/enforcement events into one dated feed.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
limitNoMaximum number of combined timeline events to return
companyYesCompany name to build the timeline for
verboseNoWhen false (default), suppress the inline alias dump and collapse per-dataset data_freshness to a single top-level as_of. Set true for the full block.

TDQS

A4.1/5.0
Behavior4/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare read-only and idempotent hints, so safety is covered. The description adds valuable behavioral context: reverse-chronological ordering, combination of six event types, and inclusion of linked subsidiaries. This goes beyond what annotations provide, giving a concrete sense of the tool's output nature.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

A single dense sentence conveys the full purpose without fluff. Information is front-loaded with the main verb and object. Every clause is meaningful, so conciseness is excellent.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness3/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

The tool is complex (aggregates six event types, includes subsidiaries), and there is no output schema. The description explains what the tool does but not the structure of the dated feed, event format, or how subsidiaries are resolved. It is minimally complete but misses some return-value details an agent might need.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100%: all three parameters (company, limit, verbose) have adequate descriptions. The tool description does not add parameter-specific detail beyond the schema, so it stays at the baseline. No missing parameter information needs compensating.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description starts with a specific verb ('Build') and resource ('compliance timeline'), and clearly distinguishes from siblings by noting it aggregates multiple event types (inspections, warning letters, import alerts, etc.) into one feed. This differentiates it from the individual search tools in the sibling list.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description clearly states the tool's scope: one company and any linked subsidiaries. This implies it is the go-to for a consolidated compliance view, contrasting with individual search tools. It does not name explicit alternatives or exclusions, but the context is clear enough for an agent to decide when to use it.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A4.1/5.0
Disambiguation4/5

Most tools have distinct purposes with clear boundaries, such as fda_search_drugs for drug applications and fda_search_510k for device clearances. However, some overlap exists, like fda_device_udi and fda_device_udi_lookup both querying UDI data, which could cause confusion despite differences in scope.

Naming Consistency5/5

All tool names follow a consistent snake_case pattern with a clear fda_ prefix, using descriptive verbs like search, get, list, and link. This uniformity makes the set predictable and easy to navigate, with no deviations in naming style.

Tool Count2/5

With 48 tools, the count is excessive for a single server, making it overwhelming and difficult for agents to manage. While the domain is broad (FDA data), the toolset feels bloated with many specialized or overlapping tools that could be consolidated.

Completeness5/5

The toolset provides comprehensive coverage of FDA data domains, including drugs, devices, inspections, compliance, recalls, and facilities. It supports full CRUD-like operations (e.g., search, get, link, save) and lifecycle workflows, with no obvious gaps for the intended purpose.

Resources